Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of cancer.~* The disease may be a solid tumor, Lymphoma or Multiple Myeloma. Pathology reports will be documented in the patient's chart and included in the data.~* Age \> 18 years~* An acute, radiographically confirmed, de novo Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)~* No past medical history of a prior thrombus or known thrombophilia~Exclusion Criteria~* Patients are not eligible for this study if they receive therapeutic doses of any heparin for more than 72 hours before randomization 31.~* Already receiving oral anticoagulant therapy 31.~* Severe renal impairment, calculated using the Cockcroft-Gault formula, defined as a creatinine clearance \<30 mL/min 31.~* Platelet count of less than 50,000 per cubic millimeter~* Bleeding from the gastrointestinal tract that requires blood transfusion (s), intracranial bleeding or retroperitoneal bleeding.~* An indication for thrombolysis~* Allergy to iodine~* Hereditary thrombophilia~* Pregnancy~* Likelihood of noncompliance~* It is contraindicated to anticoagulate patients with brain metastasis secondary to melanoma, choriocarcinoma, renal cell and medullary thyroid carcinoma. If these patients have a Venous Thromboembolism (VTE), it is standard of care for these patients to have a CT of their head to evaluate if there is metastasis to the brain before they are anticoagulated 38. If these patients do have brain metastasis, they will not be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1- Arixtra Alone (Type: EXPERIMENTAL): Arixtra Alone
- 2 Arixtra+ filter (Type: ACTIVE_COMPARATOR): Arixtra + filter

Based on this trial design, predict the completion outcome and termination type (if applicable).